AIM2 and stroke disorder: Notably, as displayed in Figure 6a,b, consistent with the results of the cognitive function tests, PBM‐treated stroke mice showed an apparent reduction of AIM2+/caspase‐1+ expression in the hippocampus and cortex (hippocampus: 452.82 ± 85.75% vs 634.41 ± 118.56%, stroke/PBM and stroke/control group, respectively; cortex: 938.96 ± 209.33% vs 4295.28 ± 634.35%, stroke/PBM and stroke/control group, respectively, p < 0.001).